Explore Hub
Comprehensive coverage and timeline for Fda Drug. Aggregated from 20 sources with 25 articles.
25 articles · 20 sources · Coverage since 4/2/2026
How Fda Drug coverage has developed over time.
Topics frequently covered alongside Fda Drug.
• The FDA has approved a landmark drug designed to treat pancreatic cancer, one of the deadliest forms of the disease. • The medication utilizes a new therapeutic approach by blocking a specific protein that fuels tumor growth in the vast majority of pancreatic cancer cases. • This approval is significant because the drug has demonstrated a measurable ability to improve patient survival rates.
npr.org• The U.S. FDA has granted speedy approval to a groundbreaking pancreatic cancer drug developed by Revolution Medicines. • In a large-scale trial, the therapy demonstrated the ability to double the survival rate for patients suffering from advanced, metastatic disease. • The drug was one of the first to utilize a new expedited FDA review process, which reduces approval timelines from 10-12 months to just one or two months for urgent health priorities.
cnn.com• Researchers analyzed the impact of the 21st Century Cures Act, which allows the FDA to approve novel drugs based on a single pivotal trial rather than multiple studies. • Findings indicate that since 2016, the number of studies supporting new drug approvals in the US has steadily decreased. • This shift reflects a trend toward increased FDA flexibility and a higher reliance on industry-funded data to accelerate the drug approval process.
cancertherapyadvisor.com• The U.S. Food and Drug Administration (FDA) has approved a new daily pill developed by Revolution Medicines for the treatment of pancreatic cancer. • This groundbreaking medication introduces a novel therapeutic approach to combat one of the most lethal forms of cancer. • The approval is significant as it provides patients with a new targeted option for managing a disease known for its high mortality rate and limited treatment efficacy.
apnews.com• A new analysis reveals that more than two-thirds of new drugs approved by the FDA in 2024 were sanctioned based on the findings of a single study. • The report indicates a steady decline in the number of studies required for drug approval since 2016, raising concerns about the rigor of the process. • Researchers argue that this trend necessitates stronger post-market surveillance and more comprehensive trial reporting to maintain the integrity of drug approvals.
cidrap.umn.edu• The US Food and Drug Administration (FDA) has granted expedited approval to daraxonrasib, a first-of-a-kind oral medication designed to treat the most common form of pancreatic cancer. • Developed by Revolution Medicines, the drug functions as a Ras multiselective inhibitor, targeting specific genetic drivers of the disease. • This approval is significant because it provides patients with a more effective treatment option for one of the deadliest types of cancer, which often has limited therapeutic alternatives.
theguardian.comFDA officials approve first-of-a-kind pill called daraxonrasib to fight one of the deadliest types of cancerThe US Food and Drug Administration (FDA) approved a groundbreaking new drug for the most common form of pancreatic cancer, offering US patients a more effective treatment against one of the deadliest types of the disease.FDA officials gave expedited approval to the first-of-a-kind pill, called daraxonrasib, that blocks a mutated protein that fuels tumor growth in more than 90% of pancreatic cancer cases. It’s an approach that has eluded drugmakers for decades. Continue reading...
theguardian.com
Image: Statnews• The FDA has granted approval for a new narcolepsy medication developed by Takeda Pharmaceutical. • In a significant medical milestone, the first-ever mRNA-based influenza vaccine has also received FDA approval. • These approvals highlight the expanding utility of mRNA technology beyond COVID-19 and provide new treatment options for sleep disorders.
statnews.com
Image: Statnews• The FDA has approved Replimune’s treatment for advanced melanoma, marking a significant victory for the company and patient advocates. • The drug's approval follows a tumultuous process in which it was previously rejected by the agency twice before clearing an advisory committee last week. • This decision provides a critical new therapeutic option for patients suffering from advanced stages of skin cancer.
statnews.com
Image: Statnews• An FDA advisory committee has voted in favor of RP1, an experimental melanoma drug developed by Replimune, despite the therapy being rejected in April. • The decision comes during a review meeting where experts evaluated the drug's efficacy and safety for treating melanoma patients. • This endorsement marks a significant reprieve for Replimune, potentially reversing a previous regulatory setback under new FDA leadership.
statnews.com